The treatment landscape of polycythemia vera (PV) has seen major advancements within the last decade including approval of ruxolitinib in the second line setting after hydroxyurea, ropegylated interferon-α2b, and advanced clinical development of a novel class of agents called hepcidin mimetics.
井哥儿
爱静静
不懈奋进
1257
stuffmatter
热切菩萨
梦之凌云
从容芮
Yziii
HEIKU
哎嘿
Leonardi
pcr163
可言飞舞
我不爱池鱼
超文献
shinysparrow
pluto
Singularity
spark810
皖公网安备34019202002308
